The oral administration of rofecoxib resulted in a significant increase in blood levels of 20-hydroxyeicosatetraenoic acid, a potent vasoconstrictor, and this metabolite was also shown to significantly decrease tail bleeding times in a mouse model. Heartwire
Read from Source
|
